PARP Inhibitors in Newly Diagnosed and Recurrent Ovarian Cancer

*Department of Gynecological, Obstetrical, and Urological Sciences, “Sapienza” University of Rome, Rome, Italy

†Department of Woman’s and Child’s Health, Obstetrics and Gynecological Unit, San Camillo-Forlanini Hospital, Rome, Italy

A.G. and C.D.D are co-first authors

C.D.D. and I.C.: Conceptualization; All authors: Methodology, data extraction, project administration, and writing—review and editing; V.D.D. G.B., and L.M.: Supervision; A.G and OD: writing—original draft.

The authors declare no conflicts of interest.

Correspondence: Camilla Di Dio, MD, Department of Gynecological, Obstetrical and Urological Sciences, “Sapienza” University of Rome, Italy - Policlinico Umberto I, Viale Regina Elena, 328, 00161 Roma, RM. E-mail: [email protected].

Comments (0)

No login
gif